Loading...
XNAS
SPRB
Market cap3mUSD
Jul 11, Last price  
0.09USD
1D
21.92%
1Q
-69.42%
IPO
-99.48%
Name

Spruce Biosciences Inc

Chart & Performance

D1W1MN
No data to show
P/E
P/S
0.37
EPS
Div Yield, %
Shrs. gr., 5y
51.07%
Rev. gr., 5y
%
Revenues
10m
0000010,089,000
Net income
-48m
L+6.30%
-9,858,000-13,237,000-30,026,000-42,688,000-45,077,000-47,919,000
CFO
-33m
L-20.17%
-8,570,000-12,617,000-27,519,000-35,877,000-41,683,000-33,275,000
Earnings
Aug 11, 2025

Profile

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
IPO date
Oct 09, 2020
Employees
32
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
10,089
 
Cost of revenue
111,514
47,712
Unusual Expense (Income)
NOPBT
(101,425)
(47,712)
NOPBT Margin
Operating Taxes
(1,103)
Tax Rate
NOPAT
(101,425)
(46,609)
Net income
(47,919)
6.30%
(45,077)
5.60%
Dividends
Dividend yield
Proceeds from repurchase of equity
53,616
(241)
BB yield
-47.52%
0.93%
Debt
Debt current
1,873
1,622
Long-term debt
4,006
5,815
Deferred revenue
Other long-term liabilities
236
161
Net debt
(90,460)
(17,105)
Cash flow
Cash from operating activities
(33,275)
(41,683)
CAPEX
(7)
(8)
Cash from investing activities
55,777
23,692
Cash from financing activities
49,140
(241)
FCF
(101,206)
(46,530)
Balance
Cash
96,339
79,077
Long term investments
(54,535)
Excess cash
95,835
24,542
Stockholders' equity
(197,228)
(149,868)
Invested Capital
278,582
224,691
ROIC
ROCE
EV
Common stock shares outstanding
38,510
23,527
Price
2.93
166.99%
1.10
-75.39%
Market cap
112,835
337.03%
25,819
-75.22%
EV
22,375
8,714
EBITDA
(101,355)
(47,638)
EV/EBITDA
Interest
483
420
Interest/NOPBT